Clinical Trial Update: 64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer [NA]

View source ↗

Summary

Clinical trial evaluating 64Cu DOTA-Trastuzumab PET/CT imaging in patients with gastric cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Gastroesophageal Junction
• Gastric Cancer

Drugs mentioned

• 64Cu DOTA-Trastuzumab PET/CT (trastuzumab)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach | NA | Status: COMPLETED | Results posted: 2019-10-08